1-12 of 12
David Olmos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, Sebastien J. Hotte, Ernesto Korbenfeld, Gero Kramer, Neeraj Agarwal, Kim N. Chi, Simon Dearden, Christopher Gresty, Jinyu Kang, Christian Poehlein, Elizabeth A. Harrington, Maha Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 92–99.
https://doi.org/10.1158/1078-0432.CCR-21-3577
Published: 04 January 2023
View article titled, Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <em>BRCA1, BRCA2</em>, or <em>ATM</em> Alterations Identified by Testing Circulating Tumor DNA
Open the PDF for Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <em>BRCA1, BRCA2</em>, or <em>ATM</em> Alterations Identified by Testing Circulating Tumor DNA in another window
Includes: Supplementary data
Journal Articles

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 81–91.
https://doi.org/10.1158/1078-0432.CCR-22-0931
Published: 04 January 2023
View article titled, Detection of <em>BRCA1</em>, <em>BRCA2</em>, and <em>ATM</em> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Open the PDF for Detection of <em>BRCA1</em>, <em>BRCA2</em>, and <em>ATM</em> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound in another window
Includes: Supplementary data
Journal Articles

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Joaquin Mateo, David Olmos, Niven Mehra, Michael P. Kolinsky, Guilhem Roubaud, Mustafa Özgüroǧlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1518–1530.
https://doi.org/10.1158/1078-0432.CCR-21-3940
Published: 14 April 2022
View article titled, Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Open the PDF for Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib) in another window
Includes: Supplementary data
Journal Articles

Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease

Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stéphane Oudard, Felix Y. Feng, Yashoda Rajpurohit, Karen Urtishak, Deborah S. Ricci, Brendan Rooney, Angela Lopez-Gitlitz, Margaret Yu, Alexander W. Wyatt, Mark Li, Gerhardt Attard, Eric J. Small
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4539–4548.
https://doi.org/10.1158/1078-0432.CCR-21-0358
Published: 15 August 2021
View article titled, Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Open the PDF for Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Carlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, Caly Chien, Hiroji Uemura, David Olmos, Paul Mainwaring, Ji Youl Lee, Margaret K. Yu, Juan Jose Perez-Ruixo, Matthew R. Smith, Eric J. Small
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (17): 4460–4467.
https://doi.org/10.1158/1078-0432.CCR-20-1041
Published: 01 September 2020
View article titled, Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Open the PDF for Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer in another window
Journal Articles

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

Anthony W. Tolcher, Khurum Khan, Michael Ong, Udai Banerji, Vassiliki Papadimitrakopoulou, David R. Gandara, Amita Patnaik, Richard D. Baird, David Olmos, Christopher R. Garrett, Jeffrey M. Skolnik, Eric H. Rubin, Paul D. Smith, Pearl Huang, Maria Learoyd, Keith A. Shannon, Anne Morosky, Ernestina Tetteh, Ying-Ming Jou, Kyriakos P. Papadopoulos, Victor Moreno, Brianne Kaiser, Timothy A. Yap, Li Yan, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 739–748.
https://doi.org/10.1158/1078-0432.CCR-14-1901
Published: 16 February 2015
View article titled, Antitumor Activity in <em>RAS</em>-Driven Tumors by Blocking AKT and MEK
Open the PDF for Antitumor Activity in <em>RAS</em>-Driven Tumors by Blocking AKT and MEK in another window
Includes: Supplementary data
Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5663–5671.
https://doi.org/10.1158/1078-0432.CCR-14-0719
Published: 13 November 2014
View article titled, Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Open the PDF for Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study in another window
Includes: Supplementary data
Journal Articles

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Timothy A. Yap, Li Yan, Amita Patnaik, Nina Tunariu, Andrea Biondo, Ivy Fearen, Kyriakos P. Papadopoulos, David Olmos, Richard Baird, Liliana Delgado, Ernestina Tetteh, Robert A. Beckman, Lisa Lupinacci, Ruth Riisnaes, Shaun Decordova, Simon P. Heaton, Karen Swales, Nandita M. deSouza, Martin O. Leach, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5672–5685.
https://doi.org/10.1158/1078-0432.CCR-14-0868
Published: 13 November 2014
View article titled, Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Open the PDF for Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cells: A Multifunctional Biomarker

Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2553–2568.
https://doi.org/10.1158/1078-0432.CCR-13-2664
Published: 14 May 2014
View article titled, Circulating Tumor Cells: A Multifunctional Biomarker
Open the PDF for Circulating Tumor Cells: A Multifunctional Biomarker in another window
Journal Articles

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

André T. Brunetto, Joo Ern Ang, Rohit Lal, David Olmos, L. Rhoda Molife, Rebecca Kristeleit, Ann Parker, Isabel Casamayor, Muyibat Olaleye, Anna Mais, Bernhard Hauns, Vera Strobel, Bernd Hentsch, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5494–5504.
https://doi.org/10.1158/1078-0432.CCR-13-0735
Published: 01 October 2013
View article titled, First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen K. Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5188–5196.
https://doi.org/10.1158/1078-0432.CCR-10-3019
Published: 31 July 2011
View article titled, Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials
Open the PDF for Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials in another window
Includes: Supplementary data
Journal Articles

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

David Olmos, Douglas Barker, Rohini Sharma, Andre T. Brunetto, Timothy A. Yap, Anne B. Taegtmeyer, Jorge Barriuso, Hanine Medani, Yan Y. Degenhardt, Alicia J. Allred, Deborah A. Smith, Sharon C. Murray, Thomas A. Lampkin, Mohammed M. Dar, Richard Wilson, Johann S. de Bono, Sarah P. Blagden
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3420–3430.
https://doi.org/10.1158/1078-0432.CCR-10-2946
Published: 15 May 2011
View article titled, Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
Open the PDF for Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data